Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models.
Alexandre Doussot, Mithat Gonen, Jimme K Wiggers...
https://pubmed.ncbi.nlm.nih.gov/27296525/Actively Recruiting
Led by Rutgers, The State University of New Jersey · Updated on 2026-03-20
30
Participants Needed
2
Research Sites
52 weeks
Total Duration
Researchers are evaluating liver transplantation as a treatment option for patients with biologically responsive locally advanced non-metastatic intrahepatic cholangiocarcinoma iCCA who have undergone neoadjuvant systemic therapy. This study aims to compare overall survival rates of these patients after liver transplantation to historical outcomes of patients treated only with chemotherapy. Intrahepatic cholangiocarcinoma is a primary liver cancer with poor survival rates following surgical resection due to high tumor recurrence. The study involves patients with locally advanced unresectable iCCA who have shown at least 6 months of disease stability or regression on neoadjuvant systemic therapy. Eligible patients are listed for liver transplantation and receive a whole liver allotransplant when a matching donor liver becomes available. This single-center phase II study tracks patients listed for transplant and compares outcomes between those who receive the transplant and those who expire or are removed from the waiting list. Participants will be closely monitored before and after transplantation, with assessment of overall survival over 5 years as the primary outcome. Secondary outcomes include recurrence-free survival, intent-to-treat overall survival, and post-transplant functional assessments to identify complications and morbidities. Follow-up includes evaluations for tumor progression, monitoring of adverse events, and compliance with study procedures, with total participation lasting up to 5 years.
CONDITIONS
Liver Transplantation in Intrahepatic Cholangiocarcinoma
M
Melissa Lugardo
A
Angenie Preval, PA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Rutgers, The State University of New Jersey
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At least 6 months
Participants with locally advanced unresectable intrahepatic cholangiocarcinoma receive neoadjuvant systemic therapy and are monitored for at least 6 months of disease stability or regression before liver transplantation.
Regular monitoring visits as part of neoadjuvant therapy
Duration - Single day procedure with immediate post-operative care
Participants who meet transplant listing criteria undergo liver transplantation when a donor liver becomes available.
1 transplant procedure visit
Duration - Up to 5 years
Participants are followed after liver transplantation to assess recovery, monitor for complications, and evaluate recurrence and survival outcomes.
Multiple follow-up visits over 5 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Alexandre Doussot, Mithat Gonen, Jimme K Wiggers...
https://pubmed.ncbi.nlm.nih.gov/27296525/Apurva Jain, Lawrence N Kwong, Milind Javle
https://pubmed.ncbi.nlm.nih.gov/27658789/Parissa Tabrizian, Ghalib Jibara, Jaclyn F Hechtman...
https://pubmed.ncbi.nlm.nih.gov/25395176/Silke Schüle, Annelore Altendorf-Hofmann, Frank Uteß...
https://pubmed.ncbi.nlm.nih.gov/23053456/E A Eisenhauer, P Therasse, J Bogaerts...
https://pubmed.ncbi.nlm.nih.gov/19097774/Jesus M Banales, Vincenzo Cardinale, Guido Carpino...
https://pubmed.ncbi.nlm.nih.gov/27095655/Yizhou Wang, Jun Li, Yong Xia...
https://pubmed.ncbi.nlm.nih.gov/23358969/Rahul Gupta, Jyoti Gupta
https://pubmed.ncbi.nlm.nih.gov/27997682/Johnny C Hong, Henrik Petrowsky, Fady M Kaldas...
https://pubmed.ncbi.nlm.nih.gov/21463781/Debra Sudan, Arnaud DeRoover, Srinath Chinnakotla...
https://pubmed.ncbi.nlm.nih.gov/12243499/Rutgers, The State University of New Jersey
Lead Sponsor